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Abstract 
Introduction: Pentoxifylline is a xanthine derivative with potential cardiovascular 
benefits.  
Aim: To evaluate the impact of pentoxifylline on blood pressure and plasma tumor 
necrosis factor-α, C-reactive protein and interleukin-6 through a systematic review and 
meta-analysis of randomized controlled trials. 
Methods: The protocol was registered (PROSPERO: CRD42016035988). The search 
included PUBMED, ProQuest, Scopus, and EMBASE until September 1st 2015 to 
identify trials reporting blood pressure or inflammatory markers during pentoxifylline 
therapy. Quantitative data synthesis was performed using a random-effects model, with 
weighted mean difference and 95% confidence intervals as summary statistics.  
Results: 15 studies (16 treatment arms) were found to be eligible for inclusion. Meta-
analysis did not suggest any effect of pentoxifylline on either systolic or diastolic blood 
pressure. Pentoxifylline treatment was associated with a significant reduction in plasma 
concentrations of tumor necrosis factor-α (weighted mean difference: -1.03 pg/mL, 95% 
confidence interval: -1.54, -0.51, p < 0.001, 11 treatment arms) and C-reactive protein 
(weighted mean difference: -1.39 mg/L, 95% confidence interval: -2.68, -0.10, p = 
0.034, 5 treatment arms). No alteration in plasma interleukin-6 concentration was 
observed. The impact of pentoxifylline on plasma tumor necrosis factor-α levels was 
found to be positively associated with treatment duration (slope: 0.031; 95% confidence 
interval: 0.004, 0.057; p = 0.023) but independent of pentoxifylline dose (slope: -
0.0003; 95% confidence interval: -0.002, 0.001; p = 0.687).  
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Conclusions: Pentoxifylline did not alter blood pressure or plasma interleukin-6 
concentration, but significantly reduced circulating tumor necrosis factor-α and C-
reactive protein concentrations. 
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Condensed abstract 
Pentoxifylline is a xanthine derivative with potential cardiovascular benefits. This study 
evaluated the impact of pentoxifylline on blood pressure, plasma tumor necrosis factor-
α, C-reactive protein and interleukin-6 through a systematic review and meta-analysis of 
randomized controlled trials. No effect of pentoxifylline on either systolic or diastolic 
blood pressure or interleukin-6 was observed. Pentoxifylline treatment was associated 
with a statistically significant reduction in plasma concentrations of tumor necrosis 
factor-α and C-reactive protein. The impact of pentoxifylline on plasma tumor necrosis 
factor-α levels was found to be positively associated with treatment duration but 
independent of pentoxifylline dose. 
 
No. of words: 95 
 
INTRODUCTION 
Pentoxifylline is a methylxanthine derivative and a non-selective 
phosphodiesterase inhibitor with hemorheological activity. Its primary use is for treating 
the symptoms of claudication, a manifestation of peripheral artery disease which results 
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in muscle pain [1]. In common with other methylxanthines such as theobromine, 
aminophylline, theophylline and caffeine, many of the pharmacological activities of 
pentoxifylline can be explained by inhibition of phosphodiesterases [2]. This group of 
enzymes is responsible for the breakdown of the intracellular second-messengers, cyclic 
adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Thus 
the methylxanthines increase intracellular concentrations of cAMP and cGMP in a wide 
variety of tissues [2].  Pentoxifylline increases erythrocyte flexibility, reduces blood 
viscosity, increases microcirculatory flow and tissue perfusion and decreases the 
potential for platelet aggregation and thrombus formation [3, 4]. It has been reported 
that pentoxifylline might also influence the function of immune cells and the production 
of cytokines [5, 6]. Interleukin (IL)-1 and tumor necrosis factor-alpha (TNF-α) are pro-
inflammatory cytokines involved in inflammatory diseases in humans including 
rheumatoid arthritis, inflammatory bowel disease, graft-vs-host disease and many 
others. Administration of these inflammatory cytokines in humans results in fever, 
inflammation, tissue destruction, and, in some cases, shock and death [7]. Reduction of 
the biological activities of IL-1, TNF-α and other inflammatory cytokines is an 
important target for the treatment of many pathologies. C-Reactive Protein (CRP) is a 
marker of systemic inflammation and is useful in cardiovascular risk prediction [8, 9]. 
The increasing recognition of the role of inflammation in atherosclerosis, has led to the 
development and testing of anti-inflammatory agents for the prevention of 
cardiovascular events [10].  
Experimental and animal studies have shown that pentoxifylline administration 
causes immune modulation in a dose-dependent manner. This is exemplified by 
increased leukocyte deformability and chemotaxis, decreased endothelial leukocyte 
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adhesion, neutrophil degranulation, TNF-α production and NK cell activity [5, 11, 12]. 
Moreover, pentoxifylline is able to suppress the synthesis of TNF-α in cell cultures, 
and in vivo, and to protect experimental animals against endotoxin shock [13]. At high 
concentrations, pentoxifylline has been shown to suppress TNF-α production by 
stimulating alveolar macrophages. However, in the same study, pentoxifylline did not 
affect the production of IL-1β, IL-6 or GM-CSF. In peripheral blood monocyte cultures 
it  inhibited  the production of TNF-α and GM-CSF, at all concentrations which were 
tested [14].  
Phosphodiesterase inhibitors such as pentoxifylline cause a range of 
physiological changes which have the potential to modulate blood pressure. Clinical 
trials have shown variable effects of phosphodiesterase inhibitors in humans on 
systemic arterial blood pressure, with most trials finding little or no effect [15]. 
However, trials may have been underpowered to detect such a difference. 
Because of the inconsistent data in published studies, we have performed the 
present meta-analysis to evaluate the impact of oral pentoxifylline therapy on systemic 
arterial blood pressure and on pro-inflammatory cytokines, when compared with 
placebo in randomized clinical trials. We discuss the possible future implications of 
therapy using pentoxifylline as an anti-inflammatory drug.   
 
METHODS  
Search Strategy 
This study was designed according to the guidelines of the 2009 preferred 
reporting items for systematic reviews and meta-analysis (PRISMA) statement [16] and 
was registered in the PROSPERO database (CRD42016035988). SCOPUS 
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(http://www.scopus.com), Medline (http://www.ncbi.nlm.nih.gov/pubmed), and 
ProQuest (http://www.proquest.com) and EMBASE (http://www.embase.com) 
databases were searched using the following search terms in titles and abstracts (and in 
combination with MESH terms in Pubmed/Medline): ("blood pressure" OR systolic OR 
diastolic OR SBP OR DBP OR hypertension OR hypertensive OR hypotension OR 
hypotensive OR anti-hypertensive) AND (pentoxifylline OR oxpentifylline OR torental 
OR trental OR agapurin OR oxpentifylline OR PENTOX OR PENTOXIL OR 
FLEXITAL). The wild-card term ‘‘*’’ was used to increase the sensitivity of the search 
strategy. No language restrictions were used in the literature search. The search was 
limited to studies in human. The literature was searched from inception to September 1st 
2015. Two reviewers evaluated each article separately. Disagreements were resolved by 
agreement and discussion with a third party. The bibliographies of selected articles were 
hand searched to identify further relevant studies. 
   
Study Selection 
Original studies were included if they met the following inclusion criteria: (i) 
being a randomized controlled trial with either parallel or cross-over design, (ii) 
investigating the impact of oral pentoxifylline on at least one of the biomarkers of 
systemic inflammation including serum/plasma CRP and pro-inflammatory cytokines or 
blood pressure iii) presenting sufficient information on baseline and end-trial 
concentrations (or differences) of inflammatory parameters in both pentoxifylline and 
control groups. Exclusion criteria were (i) non-clinical studies, (ii) uncontrolled trials, 
iii) trials with a treatment duration of < 2 weeks, and iv) administration of pentoxifylline 
in the parenteral form. 
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Data extraction  
Eligible studies were reviewed and the following data were abstracted: 1) first 
author's name; 2) year of publication; 3) study location; 4) inclusion criteria; 5) number 
of participants in the pentoxifylline and control groups; 6) age, gender and body mass 
index (BMI) of study participants; 7) circulating concentrations of CRP and pro-
inflammatory cytokines at baseline and at the end of treatment; 8) systolic and diastolic 
blood pressures; and 9) prevalence of smoking, type 2 diabetes, dyslipidemia, 
hypertension and CHD.  
 
Quality assessment 
A systematic assessment of bias in the included studies was performed using the 
Cochrane criteria [17]. The items used for the assessment of each study were as follows: 
adequacy of sequence generation, allocation concealment, blinding of subjects and 
personnel, blinding of outcome assessment, treatment of dropouts (incomplete outcome 
data), selective outcome reporting, and other potential sources of bias. According to the 
recommendations of the Cochrane Handbook, a judgment of “yes” indicated low risk of 
bias, while “no” indicated high risk of bias. Labeling an item as “unclear” indicated an 
unclear or unknown risk of bias. 
 
Quantitative Data Synthesis 
Meta-analysis was conducted using the Comprehensive Meta-Analysis (CMA) 
V2 software (Biostat, NJ) [18].  Plasma concentrations of CRP and pro-inflammatory 
cytokines were collated in mg/L and pg/mL, respectively. Systolic and diastolic blood 
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pressure were recorded as mmHg. Standard deviations (SDs) of the mean difference 
were calculated using the following formula: SD = square root [(SDpre-treatment)2 + 
(SDpost-treatment)2 – (2R × SDpre-treatment × SDpost-treatment)], assuming a correlation 
coefficient (R) = 0.5. When studies reported SEM, SD was estimated using the 
following formula: SD = SEM × sqrt (n), where n is the number of subjects. 
Net changes in measurements (change scores) were calculated for parallel trials, 
as follows: (measure at end of follow-up in the treatment group − measure at baseline in 
the treatment group) − (measure at end of follow-up in the control group − measure at 
baseline in the control group). A random-effects model and the generic inverse variance 
method were used to compensate for the heterogeneity of studies in terms of design, 
pentoxifylline dose, duration of treatment, and demographic characteristics of individual 
trials (underlying disease, age, gender and etc). In order to avoid double-counting of 
subjects and consequent unit-of-analysis error the trials with more than 1 treatment arm, 
the control group was evenly (where possible) divided into appropriate subgroups. 
Effect size was expressed as weighed mean difference (WMD) and 95% confidence 
interval (CI). In order to evaluate the influence of each study on the overall effect size, 
sensitivity analysis was conducted using the leave-one-out method (i.e. removing one 
study each time and repeating the analysis). 
 
Meta-regression 
Random-effects meta-regression was performed using unrestricted maximum 
likelihood method to evaluate the association between calculated WMD in plasma 
concentrations of inflammatory factors with dose and duration of treatment with 
pentoxifylline.  
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Publication bias 
Potential publication bias was explored using visual inspection of Begg’s funnel 
plot asymmetry, and Begg’s rank correlation and Egger’s weighted regression tests. 
Duval & Tweedie “trim and fill” method was used to adjust the analysis for the effects 
of publication bias [19]. 
 
RESULTS 
Search results and trial flow 
The searches uncovered 314 articles. The initial screening for potential 
relevance removed 295 articles in whose titles and/or abstracts were obviously 
irrelevant. Among the 19 full text articles assessed for eligibility, 4 papers were 
excluded for the following reasons:  non-clinical studies (n=1), uncontrolled trials 
(n=1), trials with a treatment duration of < 2 weeks (n=1), administration of 
pentoxifylline in the parenteral form (n=1) (Figure 1).  
 
Characteristics of included studies 
After assessment, 15 RCTs achieved the inclusion criteria and were used for the 
final meta-analysis [20-34] and these reported 18 treatment arms. A total of 739 
individuals participated in the selected trials and 377 of them were allocated to the 
pentoxifylline group and 362 subjects to control group. The number of participants in 
these trials ranged from 23 to 100. Included studies were published between 1998 and 
2015, and were conducted in South Africa (3 studies), USA (3 studies), Spain (2 
studies), Germany, India, Brazil, Turkey, Iran, and Egypt. All the studies used 400 or 
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600 mg pentoxifylline tablets and the doses ranged from 400 mg/day to 1200 mg/day. 
Duration of treatment with pentoxifylline ranged between 1 month and 12 months. All 
trials were designed as parallel-group studies. Baseline and demographic characteristics 
of included studies are summarized in Table 1. 
 
Quality assessment 
Some of the studies included reported insufficient information about the random 
sequence generation and allocation concealment. The majority of selected studies were 
double-blind, although five trials [21, 22, 25, 27, 28] were not blinded. Details of the 
quality assessment are shown in Table 2. 
 
Quantitative data synthesis 
Overall, the impact of pentoxifylline treatment on plasma concentrations of 
TNF-α [20, 22, 25, 28, 30-34], CRP [21, 25-27, 32] and IL-6 [20, 23, 26, 33] was 
reported in 11, 5 and 5 treatment arms, respectively. Meta-analysis showed a significant 
effect of pentoxifylline treatment in reducing plasma concentrations of TNF-α (WMD: -
1.03 pg/mL, 95% CI: -1.54, -0.51, p < 0.001) (Figure 2) and CRP (WMD: -1.39 mg/L, 
95% CI: -2.68, -0.10, p = 0.034) (Figure 3). However, no significant alteration was 
observed in plasma IL-6 concentrations following pentoxifylline treatment (WMD: 1.17 
pg/mL, 95% CI: -1.28, 3.62, p = 0.350) (Figure 4). The meta-analyses on changes in 
plasma TNF-α and IL-6 concentrations were robust in the leave-one-out sensitivity 
analysis; however, the meta-analysis of CRP concentrations was sensitive to studies by 
Maiti et al.[27], Sliwa et al. [32], Demir et al.[21] and Goicochea et al. [25] (Figure 3, 
lower panel).  
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Meta-analysis of 9 RCTs (10 treatment arms) [20, 21, 24, 25, 28-32] did not suggest any 
significant effect of pentoxifylline on SBP (WMD: 0.82 mmHg, 95% CI: -1.70, 3.34, p 
= 0.523) (Figure 5). Meta-analysis of 8 RCTs (9 treatment arms) [20, 21, 24, 25, 28, 29, 
31, 32]  did not suggest any significant effect of pentoxifylline on DBP (WMD: 0.09 
mmHg, 95% CI: -1.29, 1.47, p = 0.895) (Figure 6). Both analyses (SBP and DBP) were 
robust in the leave-one-out sensitivity analysis (Figures 5 and 6, lower plots). Because 
the trial conducted by Goicochea et al. [25] was the only trial to report the change in BP 
after pentoxifylline treatment in a hypertensive population (Mean SBP >140 mmHg), 
we repeated this analysis with the data from Goicochea et al. excluded. Thus, the effects 
of pentoxifylline treatment on a population which were normal as baseline was as 
follows:  SBP: WMD = 0.91; 95% = -1.90, 3.72; p = 0.524; DBP: WMD = 0.27; 95% = 
-1.15, 1.69; p = 0.708 (Figures 5 and 6, lower plots). 
  
Meta-regression  
Meta-regression analysis was conducted to evaluate the association between 
changes in plasma TNF-α concentrations and potential confounder variables including 
dose and duration of treatment with pentoxifylline. The impact of pentoxifylline on 
plasma TNF-α levels was found to be positively associated with treatment duration 
(slope: 0.031; 95% CI: 0.004, 0.057; p = 0.023) but independent of pentoxifylline dose 
(slope: -0.0003; 95% CI: -0.002, 0.001; p = 0.687) (Figure 7). 
  
Publication bias 
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Visual inspection of the funnel plot of the study precision (inverse SEM) by 
effect size (mean difference) suggested an asymmetry in the meta-analysis of the effect 
of pentoxifylline on plasma TNF-α concentration that was addressed by the imputation 
of 3 studies on the right side of the mean using trim-and-fill method. The imputed effect 
size was -0.95 pg/mL (95% CI: -1.45, -0.45), showing a significant effect after 
imputation of potentially missing studies. There was no sign of publication bias 
according to either Begg’s rank correlation (Kendall’s Tau with continuity correction = 
-0.11, z = 0.47, two-tailed p-value = 0.640) and Egger’s linear regression (intercept = 
0.05, 95% CI = -1.18, 1.29, t = 0.096, df = 9.00, two-tailed p = 0.926) test. Funnel plot 
of the impact of pentoxifylline treatment on plasma TNF-α concentration is illustrated 
in Figure 8. 
  
DISCUSSION 
Our meta-analysis showed that pentoxifylline treatment was associated with a 
statistically significant reduction in the concentrations of TNF-α and CRP in plasma. 
However, no significant alteration of plasma IL-6 concentrations was observed 
following pentoxifylline treatment.  
Four studies investigated the effect of pentoxifylline in patients with dilated 
cardiomyopathy with various causes (ischemic etiology in Sliwa et al. 2004 and 
Bahrmann et al. 2004; idiopathic in Sliwa et al. 1998, Skudicky et al. 2001 and 
Bahrmann et al. 2004, hypertensive in Bahrmann et al. 2004) [20, 30-32]. Sliwa et al. 
1998 investigated the effect of pentoxifylline on left ventricular performance in 
idiopathic dilated cardiomyopathy and concluded that pentoxifylline treatment reduced 
the concentration of TNF-alpha in plasma and was associated with improvement of 
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symptoms and left ventricular systolic function [31]. This was in contrast to the studies 
performed by Skudicky et al. 2001 [30] and Bahrmann et al. 2004 [20] which included 
patients with idiopathic cardiomyopathy. In these studies, treatment with pentoxifylline  
was not associated with significant changes in TNF-alpha [20, 30] and IL-6 [20] 
concentrations. Significant improvements in symptoms and left ventricular function 
were seen in one trial [30] but not the other [20]. However in this negative study, the 
results are complicated by the fact patients in this study were treated with a beta-blocker 
(carvedilol) for the 3 months prior to initiation of pentoxifylline therapy. Functional 
improvement by beta-blockers in heart failure is well documented as well as the 
potential of these drugs to reduce concentrations of circulating inflammatory cytokines 
[35]. Thus a ‘ceiling’ beneficial effect may have been reached before pentoxifylline 
treatment began. 
 
In patients with ischemic cardiomyopathy, adding pentoxifylline to standard 
therapy (which included beta blockers) was associated with reduction in plasma 
concentration of inflammatory markers TNF-alpha and CRP, marker of apoptosis 
(Fas/Apo-1) and correlated with  improvement of left ventricular ejection fraction [32]. 
 
Three studies investigated the effect of pentoxifylline in patients with non-
alcoholic steatohepatitis (NASH) [22, 33, 34]. In studies conducted by Van Wagner et 
al. 2011 [33] and Zein et al. 2011 [34],  pentoxifylline treatment did not alter serum 
TNF-α, concentrations, but improved liver enzymes and histology in patients with 
NASH, but did not appear to offer substantial benefit over placebo [33] with some 
benefit in liver fibrosis at one year [34]. But pentoxifylline therapy reduced hepatic 
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expression of collagen-1, an important fibrogenic gene, and TIMP-1, which is also 
involved in fibrosis, however the latter effect was not statistically significant. Thus 
pentoxifylline could have potential benefit on fibrosis. Both studies concluded that 
pentoxifylline treatment is well tolerated [33, 34]. When pentoxifylline was added to 
fenofibrate treatment in patients with NASH (El-Haggar et al. 2015) [22], patients 
receiving both drugs showed significantly lower TNF-α concentrations than that 
detected with fenofibrate treated group. The author concluded that the combination of  
pentoxifylline and fenofibrate has a beneficial effect on liver markers of fibrosis, liver 
stiffness, insulin resistance and inflammatory pathways implicated in NASH [22].  
Two studies investigated the anti-inflammatory effect of pentoxifylline in 
patients with type 2 diabetes mellitus. In study conducted by Navarro et al in 2005, 
pentoxifylline therapy was added to angiotensin II receptor blocker (ARB) therapy in 
normotensive patients with diabetes and residual albuminuria despite adequate therapy 
with an ARB [28]. The study showed that pentoxifylline added to ARB therapy was 
associated with a significant reduction of concentrations of TNF-α in  serum and urine. 
This modulation of inflammatory responses could explain the supplementary 
antiproteinuric effect observed [28]. It has also been demonstrated that in hypertensive 
patients with type 2 diabetes mellitus pentoxifylline treatment improved inflammatory 
markers, oxidative stress and platelet-aggregation. In this trial, however, hsCRP was 
used as a marker for inflammation and TNF-α was not reported. [27] 
 
 In patients with coronary artery disease, pentoxifylline treatment has been 
shown to be associated with a statistically significant reduction in pro-inflammatory 
response (decreased CRP and TNF-α) and a trend towards increased concentrations of 
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the anti-inflammatory mediator TGF-beta1.  Although this study was small and did not 
measure clinical events, it nevertheless showed an anti-inflammatory effect of 
pentoxifylline treatment [23].  
 
The mechanisms by which phosphodiesterase inhibitors such as pentoxifylline can elicit 
anti-inflammatory effects have been comprehensively reviewed elsewhere [36, 37]. In 
particular, the inhibition of the isozyme phosphodiesterase-4 is likely to be important. 
Phosphodiesterase 4 highly expressed in inflammatory cells including neutrophils, 
macrophages, T cells and endothelial cells [38]. Insights from the respiratory system 
have shown that inhibition of phosphodiesterase 4 in immune cells and the subsequent 
elevation of cAMP results in an anti-inflammatory effect [38-40]. Specific inhibitors of 
this isoenzyme are being developed for use in the treatment of a wide range of disease 
states with an inflammatory component, including dermatological, neurological and 
respiratory conditions [38, 41-46]. With respect to the reduction in TNF-α by 
pentoxifylline observed in this study, Shaw [11] has comprehensively reviewed the 
potential mechanisms which include: Suppression of TNF-α gene transcription by 
pentoxifylline [47], attenuation of the response of TNF-α to endotoxin [48], and 
attenuation of Interleukin-2, a cytokine which stimulates TNF-α production [6], 
 
     Primarily used to treat peripheral arterial disease patients due to the improved 
circulation obtained through its ability to alter erythrocyte deformability, pentoxifylline 
also enhances capillary microcirculation [2, 11]. We examined the potential of this 
methylxanthine derivate as a blood pressure (BP) lowering agent in a range of studies, 
including those that reported its effects in hypertensive patients [20, 27] . Blood 
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pressure was similar in pentoxifylline and control groups and no significant differences 
were observed during the follow-up period in systolic blood pressure or diastolic blood 
pressure. 
 
The lack of effect of pentoxifylline on systemic arterial blood pressure seen in this study 
supports previous observations with pentoxifylline [49] and other phosphodiesterase 
inhibitors [15] where little or no effect on blood pressure was observed. It is important 
to note that in all but one of the studies which measured the effect of pentoxifylline on 
blood pressure, the participants were normotensive at baseline. It would be difficult to 
demonstrate a hypotensive effect of a drug in such a population. Nevertheless, the study 
performed by Goicochea et al.[25]  which enrolled  a hypertensive population (mean 
SBP >140 mmHg) did not demonstrate an effect of pentoxifylline on BP, and exclusion 
of this study from the meta-analysis did not affect the result.  The ubiquity of cAMP 
(and cGMP) signaling, modulated by phosphodiesterases, results in multiple and 
complex physiological effects when these enzymes are inhibited. In the vasculature, the 
accumulation of cAMP promotes vasodilation and a reduction in peripheral resistance 
[50, 51] which would be expected to be associated with a hypotensive effect. However, 
the dose required for this effect may be higher the usual clinical dose [52]. Conversely, 
in the myocardium, phosphodiesterase inhibition and elevation of cAMP have been 
shown to elicit positive chronotropic [53] and inotropic [54] responses which would be 
expected to increase blood pressure. Thus the effects of pentoxifylline in the heart and 
the vasculature would appear to have small, functionally opposite effects on blood 
pressure, and the overall effect would appear to be a ‘zero sum’. An antihypertensive 
effect of pentoxifylline would be desirable in the treatment of cardiovascular disease. 
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However, the fact that no pressor effect of pentoxifylline has been demonstrated, means 
that it can be used for its anti-inflammatory effects without concerns about an adverse 
effect on blood pressure. Further investigations into the effects of this drug on blood 
pressure in a hypertensive population are warrented.  
 
The present meta-analysis has several limitations. Most importantly, there were 
only a small number of eligible RCTs and most of them included relatively small 
populations. Furthermore, these studies were heterogeneous regarding population 
characteristics, study design, and pathology of patients involved. A conservative 
random-effects model was used to account for the heterogeneity between the studies and 
sensitivity analysis was performed to examine the impact of each individual study on 
the overall effect size.  
 
Conclusion 
In conclusion, our meta-analysis has shown a significant anti-inflammatory 
effect of pentoxifylline treatment, exemplified by reduced concentrations of TNF-α and 
CRP in plasma in a range pathologies including coronary artery disease, type 2 diabetes 
mellitus, idiopathic and ischemic cardiomyopathy and chronic kidney disease. 
Pentoxifylline treatment was associated with anti-inflammatory effects when given 
alone or when added to standard therapy. This is not a licensed indication for 
pentoxifylline. We did not detect any effect of pentoxifylline on Il-6 or systemic arterial 
blood pressure. None of the randomized controlled trials (RCT) gave any cause to doubt 
the safety of pentoxifylline treatment. This raises the possibility that pentoxifylline may 
have therapeutic benefit in diseases where inflammatory pathways (characterized by 
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elevated by TNF-α and CRP) play an important role. These may include rheumatoid 
arthritis, asthma and atherosclerotic cardiovascular disease. Further outcomes- based 
RCTs are warranted to test the effect of pentoxifylline in such circumstances. 
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100 70 66.67 69 52 NR 85 66.67 48.38 33.3 86 85.7 67 62 69.2 
BMI 
Kg/m
2) 
Ca
se  
28±3 NR 27.14 
± 1.27 
27.5±
0.7 
32.06 NR NR 26.45
±4.25 
NR 30.51
±7.13 
NR NR NR 34.0 
± 0.9 
32.9 
± 4.6 
Co
ntr
28±5 NR 27.26 
± 1.06 
27.8±
0.8 
31.84 NR NR 25.19
±3.01 
NR 30.75
±4.22 
NR NR NR 35.1 
± 2.6 
34.0 
± 5.4 
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ol 
SBP 
(mm
Hg) 
Ca
se  
125± 
12 
127 ± 
9.2 
NR NR 122.2 148 ± 
24 
NR 144.5
±12.9
5 
134.4
±  6.0 
115.6
8±11.
16 
120± 
18 
121  119±19 NR NR 
Co
ntr
ol 
118± 
13 
128 ± 
8.4 
NR NR 124.4 147 ± 
16 
NR 139.5
5±10.
39 
132.1
± 6.2 
115.2
8±9.1
5 
111± 
22 
115  117±18 NR NR 
DBP 
(mm
Hg) 
Ca
se  
77± 9 84 ± 
3.9 
NR NR 72.3 77 ± 
15 
NR 86.0±
7.70 
83.3±
6.7 
75.45
±8.15 
76 ±11 73  77±14 NR NR 
Co
ntr
ol 
73± 10 85 ± 
4.1 
NR NR 74.6 76± 
13 
NR 82.71
±6.35 
81.5 
±7.6 
77.29
±8.26 
70± 13 70  74±13 NR NR 
TNF-
α 
pg/ml 
Ca
se  
 
11± 7 4.2 ± 
2.1 
5.67±1
.24  
2.5(3.
9) * 
 
 
NR 6.6±1.
9¥ 
 
 
NR 
 
NR 
 
6.4(2.
1 to 
9.7) 
NR 2.5±1.9 
 
6.5±3.0  
 
7.0±3.4 
 
NR 7.4±2
.0  
 
 37 
Co
ntr
ol 
 9± 5 
 
4.0 ± 
2.2 
5.39±1
.04 
3.0 
(4.2) *   
NR 7±1.6¥ 
 
 
NR NR 5.1(1.
4 to 
10) 
 
NR 2.16±1.
9 
 
10.8±9.
1 
 
7.9±3.9 NR 7.6±1
.7 
 
hs -
CRP 
 
mg/l 
Ca
se 
 
NR 
 
NR NR 
 
9.6(1
9) * 
 
NR 4.7(2.
0-8.4) 
¥ 
1.78(
3.72)€ 
1.39±
0.9 
 
NR 
 
NR NR 
 
NR 
 
11.0±5.
6 
 
NR 
 
NR 
 
Co
ntr
ol 
NR 
 
 
 
NR NR 8.8(2
4) * 
 
 
 
NR 3.0(1.
8-7.5) 
¥ 
 
1.86(
2.57) 
€ 
 
1.22±
0.9 
 
 
 
 
NR 
 
NR NR NR 
 
6.9±5.7 
 
 
NR 
 
NR 
 
IL-6 
pg/ml 
 
Ca
se  
 
 
12± 30 1.81 
± 0.6 
NR 5.7(6.
8) * 
NR NR 2.61(
2.59) 
€    
 
NR NR NR NR 
 
 
 
NR 
 
 
 
NR 
 
 
 
NR NR 
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Co
ntr
ol 
7± 6 2.12 
± 0.6 
NR 4.4(6.
9) * 
 
NR NR 1.91 
(1.53) 
€ 
 
NR NR NR NR NR NR NR NR 
 
Values are expressed as mean ± SD; ≠-Values represent relative means ± SEM; *Values represent median (interquartile range); €-Values 
represent as means (standard deviation); ¥-Data are expressed as mean ± standard deviation or median (interquartile range); $ The 
trial conducted by Bahrmann et al included two treatment arms which represented two populations: Group A, Patients with ischemic 
dilated and hypertensive cardiomyopathy; Group B: Patients with idiopathic dilated cardiomyopathy.  
Abbreviations: ACEI-angiotensin converting enzyme inhibitor; ARB- angiotensin receptor blocker; BNP-brain natriuretic peptide; CRP- C 
reactive protein; GFR-glomerular filtration rate;  IL-interleukin; LVEF-left ventricle ejection fraction; NR-not reported; NYHA-
New York Heart Association; PAI-1- Plasminogen activator inhibitor-1; sTNFRI-soluble tumor necrosis factor receptor; TGF-tumor 
growth factor; TNF-tumor necrosis factor;  
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Table 2 Assessment of risk of bias in the included studies using Cochrane criteria. 
 
Study Ref Sequence 
generation 
Allocation 
concealment 
Blinding of 
participants and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other 
potential 
threats to 
validity 
Bahrmann et 
al. 2004 
[20] U U L L L L L 
Demir et al. 
2006 
[21] H H H H L L L 
El-Haggar et 
al. 2015 
[22] U U H H L L L 
Fernandes 
2008 
[23] L L L U L L L 
Ghorbani et 
al. 2012 
[24] L L U U L L L 
Goicoechea 
et al 2012 
[25] L L H H L L L 
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Gupta et 
al.2013 
[26] L L L L L L L 
Navarro et 
al. 2005 
[28] L L H H L L L 
Maiti et al. 
2007 
[27] U U H H L L L 
Shahidi et al. 
2015 
[29] L L L U L L L 
Skudicky et 
al. 2001 
[30] U U L L L L L 
Sliwa et al. 
1998 
[31] L L L L L L L 
Sliwa et al. 
2004 
[32] L L L L L L L 
Van Wagner 
et al. 2011 
[33] L L L L L L L 
Zein et al. 
2011 
[34] L L L l L L L 
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L: low risk of bias; H: high risk of bias; U: unclear risk of bias. 
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Figures 
 
Figure 1. Flow diagram of the study selection procedure. 
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Figure 2. Forest plot detailing weighted mean difference and 95% confidence intervals for 
the impact of pentoxifylline treatment on plasma TNF-α concentrations. The trial 
conducted by Bahrmann et al included two treatment arms which represented two 
populations: Group A, Patients with ischemic dilated and hypertensive cardiomyopathy; 
Group B: Patients with idiopathic dilated cardiomyopathy. 
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Figure 3. Forest plot detailing weighted mean difference and 95% confidence intervals for 
the impact of pentoxifylline treatment on plasma CRP concentrations. The lower plot 
shows the results of leave-one-out sensitivity analysis. 
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Figure 4. Forest plot detailing weighted mean difference and 95% confidence intervals for 
the impact of pentoxifylline treatment on plasma IL-6 concentrations. The trial conducted 
by Bahrmann et al included two treatment arms which represented two populations: Group 
A, Patients with ischemic dilated and hypertensive cardiomyopathy; Group B: Patients with 
idiopathic dilated cardiomyopathy. 
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Figure 5. Forest plot detailing weighted mean difference and 95% confidence intervals for 
the impact of pentoxifylline treatment on systolic blood pressure. The lower plot shows the 
results of leave-one-out sensitivity analysis. The trial conducted by Bahrmann et al 
included two treatment arms which represented two populations: Group A, Patients with 
ischemic dilated and hypertensive cardiomyopathy; Group B: Patients with idiopathic 
dilated cardiomyopathy. N.B. The result is unaffected by the exclusion of the study by 
Goicoechea which included hypertensive participants. 
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Figure 6. Forest plot detailing weighted mean difference and 95% confidence intervals for 
the impact of pentoxifylline treatment on diastolic blood pressure. The lower plot shows the 
results of leave-one-out sensitivity analysis. The trial conducted by Bahrmann et al 
included two treatment arms which represented two populations: Group A, Patients with 
ischemic dilated and hypertensive cardiomyopathy; Group B: Patients with idiopathic 
dilated cardiomyopathy. N.B. The result is unaffected by the exclusion of the study by 
Goicoechea which included hypertensive participants. 
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Figure 7. Meta-regression plots of the association of mean changes in plasma TNF-α 
concentrations with dose and duration of pentoxifylline treatment. The size of each circle is 
inversely proportional to the variance of change.  
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Figure 8. Funnel plot detailing publication bias in the meta-analysis of the impact of 
pentoxifylline treatment on plasma TNF-α concentrations. Trim and fill method was used to 
impute for potentially missing studies. Open circles represent observed published studies; 
closed circles represent imputed unpublished studies.  
 
 
